Biomerieux Shares Drop 8% Over the Week, Hindered by Downward Momentum
Biomerieux experienced a challenging week, with a decline of 8%, which starkly contrasts with the relative stability of major indices. The stock closed at 104.60 euros, further sinking into the red and widening the gap with its already negative annual performance. This trend reveals persistent selling pressure on the medical diagnostics group, far from the bullish orientation of the Parisian market.
Weekly Performance Overview
Biomerieux ended the week down by 8%, with a closing price set at 104.60 euros. This performance starkly contrasts with its environment: the CAC 40 gained 0.19% over the same period, while the SBF 120 advanced by 0.13%. The discrepancy is thus evident. Throughout 2025 to date, the stock has suffered a decline of 4.82%, indicative of a bearish trend that has been established for several months. The stock now trades well below its moving averages: the 50-day average stands at 108.18 euros, while the 200-day average is at 115.40 euros, creating a deteriorated chart configuration. Analysts have set a three-month price target of 123.74 euros, suggesting a potential upside of 17.29%, even though this hope is not enough to stem the current sales. The estimated yield for 2026 stands at 1.03%, with a dividend expected to be 1.16 euros per share.
Technical Analysis Insights
Technical analysis offers no immediate signs of stabilization. The Relative Strength Index (RSI) stands at 35, indicating a marked selling dynamic, while the MACD shows a line at -0.29, confirming the weakness of momentum. The stock is now fluctuating between its support levels at 104.20 euros and resistance at 114.80 euros, in a narrow range that limits volatility, measured at 6.23% over a month. The Bollinger Bands, positioned between 105.05 and 114.89 euros, enclose the price near their lower limit, reflecting bearish pressure. The beta ratio of -0.18 suggests a reverse sensitivity to the market, an atypical trait that may reflect specific sector dynamics of the group or a specific portfolio composition. This technical setup calls for increased vigilance, especially if the stock were to test its current supports.
